Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum
14 Juin 2023 - 2:00PM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on
transforming medicines to transform lives, today announced leader
sponsorship of the American Academy of Sleep Medicine (AASM)
Foundation’s 15th Annual Young Investigators Research Forum (YIRF).
This will be Avadel’s third year as lead sponsor of the YIRF
program, which takes place March-June 2023, with virtual events and
in-person events.
Avadel has supported AASM Foundation’s YIRF program since 2021,
and has increased support for this critical training program as
in-person training activities resume.
The AASM Foundation’s YIRF program aids the career development
of promising young investigators in clinical and translational
sleep medicine research. For 25 years, the AASM Foundation has been
the leading organization helping investigators, community leaders,
and clinicians advance the understanding of the evolving field of
sleep. The programs of the AASM Foundation support career
development, high-impact research projects, and community programs
that are “Championing a Bright Future in Sleep Health”.
“At Avadel, we’re passionate about supporting the sleep
community, including both people with sleep disorders, as well as
scientists advancing sleep research,” said Jennifer Gudeman,
PharmD, Senior Vice President, Medical and Clinical Affairs at
Avadel. “Our ongoing partnership with the AASM Foundation stems
from a communal goal to expand the field of sleep medicine for the
benefit of patients. We’re proud to support this vital training
program with hopes that future discoveries from these early career
investigators will result in new ways to better improve the lives
of those with disorder sleep conditions, like narcolepsy.”
AASM Foundation President Anita V. Shelgikar, MD, MHPE added,
“The Young Investigators Research Forum provides opportunities for
collegial interaction with investigators across the broad spectrum
of clinical sleep research, as well as exposure and dialogue with
scientific and program officers from federal funding agencies. We
are thankful for Avadel’s continued support and their sponsorship
of this program.”
To learn more about the Young Investigators Research Forum,
please visit:
https://foundation.aasm.org/award-programs/young-investigators-research-forum/
About Avadel Pharmaceuticals plcAvadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company
focused on transforming medicines to transform lives. Our approach
includes applying innovative solutions to the development of
medications that address the challenges patients face with current
treatment options. Avadel’s commercial product, LUMRYZ™, was
approved by the U.S. Food & Drug Administration (FDA) as the
first and only once-at-bedtime oxybate for the treatment of
cataplexy or excessive daytime sleepiness (EDS) in adults with
narcolepsy. For more information, please visit www.avadel.com.
About the American Academy of Sleep Medicine
Foundation:The AASM Foundation is a
not-for-profit 501(c)(3) charitable and scientific organization
that was established by the American Academy of Sleep
Medicine. Learn more about the AASM Foundation’s program portfolio
of research grants for all career stages, public awareness grants
and training programs by visitng foundation.aasm.org.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc. Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Natalie RubinoReal
Chemistrynrubino@realchemistry.com
AASM Foundation Media
Contact:media@aasm.org(630) 737-9700
Avadel Pharmaceuticals (NASDAQ:AVDL)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024